Evidence map›Paper›PMID 15113397›Full record

ArticleBMC immunology2004

Endothelial cells present antigens in vivo.

Annette L Rothermel, Yinong Wang, Jeffrey Schechner, Barry Mook-Kanamori, William C Aird, Jordan S Pober, George Tellides, David R Johnson

Open access · goldAbstract read
In one paragraph

Article in BMC immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 79 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Nanotherapeutics in transplantation: How do we get to clinical implementation?American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Review
  8. Review
  9. Review
  10. Article
  11. The Role of Immunomodulation in Vein Graft Remodeling and Failure.Journal of cardiovascular translational research · 2021
    Review
  12. Endothelial Cells in Emerging Viral Infections.Frontiers in cardiovascular medicine · 2021
    Review
  13. AdvancedFrontiers in immunology · 2021
    Review
  14. Article
  15. Vascular Endothelial Cells and Innate Immunity.Arteriosclerosis, thrombosis, and vascular biology · 2020
    Review
  16. Article
  17. Review
  18. Article
  19. Activated T-effector seeds: cultivating atherosclerotic plaque through alternative activation.American journal of physiology. Heart and circulatory physiology · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Annette L RothermelDepartment of Pathology, Interdepartmental Program in Vascular Biology and Transplantation, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA. arothermel@niaid.nih.gov
Yinong Wang
Jeffrey Schechner
Barry Mook-Kanamori
William C Aird
Jordan S Pober
George Tellides
David R Johnson
Yale University · USBeth Israel Deaconess Medical Center · US

Funding

Presentation of Alloantigen by Human Vascular CellsR01HL051014 · NHLBI · YALE UNIVERSITY · PI MANES, THOMAS DAVID, POBER, JORDAN S · 1994 to 2019
$10.4M
HUMAN CTL-MEDIATED INJURY OF GRAFT ENDOTHELIAL CELLSR01HL062188 · NHLBI · YALE UNIVERSITY · PI POBER, JORDAN S · 2000 to 2009
$3.9M
NHLBI NIH HHS HL51014NHLBI NIH HHS HL62188NHLBI NIH HHS R01 HL051014NHLBI NIH HHS R01 HL062188
6 · The paper itself

Abstract

backgroundImmune recognition of vascular endothelial cells (EC) has been implicated in allograft rejection, protection against pathogens, and lymphocyte recruitment. However, EC pervade nearly all tissues and predominate in none, complicating any direct test of immune recognition. Here, we examined antigen presentation by EC in vivo by testing immune responses against E. coli beta-galactosidase (beta-gal) in two lines of transgenic mice that express beta-gal exclusively in their EC. TIE2-lacZ mice express beta-gal in all EC and VWF-lacZ mice express beta-gal in heart and brain microvascular EC.

resultsTransgenic and congenic wild type FVB mice immunized with beta-gal expression vector DNA or beta-gal protein generated high titer, high affinity antisera containing comparable levels of antigen-specific IgG1 and IgG2a isotypes, suggesting equivalent activation of T helper cell subsets. The immunized transgenic mice remained healthy, their EC continued to express beta-gal, and their blood vessels showed no histological abnormalities. In response to beta-gal in vitro, CD4+ and CD8+ T cells from immunized transgenic and FVB mice proliferated, expressed CD25, and secreted IFN-gamma. Infection with recombinant vaccinia virus encoding beta-gal raised equivalent responses in transgenic and FVB mice. Hearts transplanted from transgenic mice into FVB mice continued to beat and the graft EC continued to express beta-gal. These results suggested immunological ignorance of the transgene encoded EC protein. However, skin transplanted from TIE2-lacZ onto FVB mice lost beta-gal+ EC and the hosts developed beta-gal-specific antisera, demonstrating activation of host immune effector mechanisms. In contrast, skin grafted from TIE2-lacZ onto VWF-lacZ mice retained beta-gal+ EC and no antisera developed, suggesting a tolerant host immune system.

conclusionResting, beta-gal+ EC in transgenic mice tolerize specific lymphocytes that would otherwise respond against beta-gal expressed by EC within transplanted skin. We conclude that EC effectively present intracellular "self" proteins to the immune system. However, antigen presentation by EC does not delete or anergize a large population of specific lymphocytes that respond to the same protein following conventional immunization with protein or expression vector DNA. These results clearly demonstrate striking context sensitivity in the immune recognition of EC, a subtlety that must be better understood in order to treat immune diseases and complications involving the vasculature.

Indexed as

Antigen PresentationAnimalsAntigen-Presenting CellsAutoantigensbeta-GalactosidaseCells, CulturedEndothelium, VascularHeart TransplantationMiceMice, TransgenicReceptor, TIE-2Skin TransplantationT-LymphocytesVacciniaVaccinia virusvon Willebrand FactorAutoantigensbeta-GalactosidaseReceptor, TIE-2von Willebrand Factor

Identifiers

PMID15113397
PMCPMC394319
OpenAlexW2126407015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.